Chroma Medicine Secures $135 Million in Series B Funding to Revolutionize Genomic Medicines

Chroma Medicine is thrilled to announce that it has successfully raised $135 million in its latest funding round, marking a significant milestone in the quest to revolutionize the field of genomic medicine. As a pioneering company focused on developing a new class of single-dose genomic therapies, Chroma harnesses the power of epigenetics, the natural mechanism that regulates gene expression, enabling precise control over cell function without altering the underlying DNA sequence. This groundbreaking approach positions Chroma at the forefront of precision genomics, allowing it to advance therapeutics that promise to transform the way a range of diseases are treated. The capital raised will be instrumental in accelerating ongoing research and development efforts, expanding clinical trials, and expediting the journey towards delivering innovative treatments to patients. Chroma Medicine's commitment to unlocking the potential of epigenetic science is rooted in cutting-edge research led by some of the most esteemed experts in the genomic medicine field. The infusion of funds will also support the expansion of the company’s talented workforce, bringing together a diverse and skilled team dedicated to shaping the future of medicine. As we embark on this exciting journey, we are reminded of the importance of safeguarding the integrity of our recruitment process and encourage potential candidates to be vigilant against fraudulent job offers. For the latest and legitimate career opportunities at Chroma Medicine, please visit the Join Us page on our website.